Overview

Janus Kinase Inhibition in Sarcoidosis

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.

Phase:

Phase 2

Details

Lead Sponsor:

Yale University

Collaborator:

Pfizer

Treatments:

Abrocitinib